Speaker illustration

Doctor Anna Sina Pettersson Meyer


Effects of interleukin-6 inhibition with ziltivekimab in patients at high risk of atherosclerotic events in Japan: results from the phase 2 RESCUE-2 trial

Event: ESC Congress 2022

Topic: Renal Failure and Cardiovascular Disease

Session: Renal failure and cardiovascular disease 2


ESC 365 is supported by

logo Novo Nordisk
logo Bristol Myers Squibb